ALK B Stock Overview
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally.
No risks detected for ALK B from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.119.30|
|52 Week High||kr.175.00|
|52 Week Low||kr.113.20|
|1 Month Change||-11.63%|
|3 Month Change||-3.17%|
|1 Year Change||-10.23%|
|3 Year Change||76.48%|
|5 Year Change||127.24%|
|Change since IPO||249.34%|
Recent News & Updates
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Calculating The Fair Value Of ALK-Abelló A/S (CPH:ALK B)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of ALK-Abelló A/S...
|ALK B||DK Pharmaceuticals||DK Market|
Return vs Industry: ALK B underperformed the Danish Pharmaceuticals industry which returned -0.7% over the past year.
Return vs Market: ALK B exceeded the Danish Market which returned -12.3% over the past year.
|ALK B volatility|
|ALK B Average Weekly Movement||5.5%|
|Pharmaceuticals Industry Average Movement||5.5%|
|Market Average Movement||5.6%|
|10% most volatile stocks in DK Market||10.3%|
|10% least volatile stocks in DK Market||2.9%|
Stable Share Price: ALK B is not significantly more volatile than the rest of Danish stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ALK B's weekly volatility (6%) has been stable over the past year.
About the Company
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies.
ALK-Abelló Fundamentals Summary
|ALK B fundamental statistics|
Is ALK B overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALK B income statement (TTM)|
|Cost of Revenue||kr.1.58b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 10, 2022
|Earnings per share (EPS)||1.44|
|Net Profit Margin||7.52%|
How did ALK B perform over the long term?See historical performance and comparison
Is ALK B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALK B?
Other financial metrics that can be useful for relative valuation.
|What is ALK B's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does ALK B's PE Ratio compare to its peers?
|ALK B PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
HLUN A H. Lundbeck
NOVO B Novo Nordisk
DPH Dechra Pharmaceuticals
ALK B ALK-Abelló
Price-To-Earnings vs Peers: ALK B is expensive based on its Price-To-Earnings Ratio (82.7x) compared to the peer average (42.2x).
Price to Earnings Ratio vs Industry
How does ALK B's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: ALK B is expensive based on its Price-To-Earnings Ratio (82.7x) compared to the European Pharmaceuticals industry average (17.5x)
Price to Earnings Ratio vs Fair Ratio
What is ALK B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||82.7x|
|Fair PE Ratio||34.2x|
Price-To-Earnings vs Fair Ratio: ALK B is expensive based on its Price-To-Earnings Ratio (82.7x) compared to the estimated Fair Price-To-Earnings Ratio (34.2x).
Share Price vs Fair Value
What is the Fair Price of ALK B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ALK B (DKK119.3) is trading below our estimate of fair value (DKK361.63)
Significantly Below Fair Value: ALK B is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is ALK-Abelló forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALK B's forecast earnings growth (34% per year) is above the savings rate (0.1%).
Earnings vs Market: ALK B's earnings (34% per year) are forecast to grow faster than the Danish market (9.2% per year).
High Growth Earnings: ALK B's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ALK B's revenue (10.7% per year) is forecast to grow faster than the Danish market (6.7% per year).
High Growth Revenue: ALK B's revenue (10.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALK B's Return on Equity is forecast to be low in 3 years time (17.4%).
Discover growth companies
How has ALK-Abelló performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALK B has high quality earnings.
Growing Profit Margin: ALK B's current net profit margins (7.5%) are higher than last year (1.5%).
Past Earnings Growth Analysis
Earnings Trend: ALK B's earnings have grown significantly by 56.3% per year over the past 5 years.
Accelerating Growth: ALK B's earnings growth over the past year (478.2%) exceeds its 5-year average (56.3% per year).
Earnings vs Industry: ALK B earnings growth over the past year (478.2%) exceeded the Pharmaceuticals industry 19.1%.
Return on Equity
High ROE: ALK B's Return on Equity (8.4%) is considered low.
Discover strong past performing companies
How is ALK-Abelló's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ALK B's short term assets (DKK2.7B) exceed its short term liabilities (DKK1.4B).
Long Term Liabilities: ALK B's short term assets (DKK2.7B) exceed its long term liabilities (DKK989.0M).
Debt to Equity History and Analysis
Debt Level: ALK B's net debt to equity ratio (4.7%) is considered satisfactory.
Reducing Debt: ALK B's debt to equity ratio has reduced from 27.5% to 10% over the past 5 years.
Debt Coverage: ALK B's debt is well covered by operating cash flow (130.1%).
Interest Coverage: ALK B's interest payments on its debt are well covered by EBIT (69.5x coverage).
Discover healthy companies
What is ALK-Abelló current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Forecast Dividend Yield
Dividend Yield vs Market
|ALK-Abelló Dividend Yield vs Market|
|Market Bottom 25% (DK)||1.8%|
|Market Top 25% (DK)||6.7%|
|Industry Average (Pharmaceuticals)||2.9%|
|Analyst forecast in 3 Years (ALK-Abelló)||1.1%|
Notable Dividend: Unable to evaluate ALK B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALK B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALK B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALK B's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: ALK B is not paying a notable dividend for the Danish market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ALK B has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Carsten Hellmann (58 yo)
Mr. Carsten Hellmann has been the Chief Executive Officer and President at ALK-Abelló A/S since May 17, 2016. Mr. Hellmann serves as the Chief Executive Officer at Merial Inc., Boehringer Ingelheim Animal...
CEO Compensation Analysis
|Carsten Hellmann's Compensation vs ALK-Abelló Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||kr.18m||kr.8m|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||kr.16m||kr.8m|
Compensation vs Market: Carsten's total compensation ($USD2.28M) is about average for companies of similar size in the Danish market ($USD2.32M).
Compensation vs Earnings: Carsten's compensation has been consistent with company performance over the past year.
Experienced Management: ALK B's management team is seasoned and experienced (5.5 years average tenure).
Experienced Board: ALK B's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
ALK-Abelló A/S's employee growth, exchange listings and data sources
- Name: ALK-Abelló A/S
- Ticker: ALK B
- Exchange: CPSE
- Founded: 1923
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr.26.314b
- Shares outstanding: 220.57m
- Website: https://www.alk.net
Number of Employees
- ALK-Abelló A/S
- Boge Alle 6-8
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ALK B||CPSE (OMX Nordic Exchange Copenhagen)||Yes||B Ordinary Shares||DK||DKK||Dec 2005|
|0OIR||LSE (London Stock Exchange)||Yes||B Ordinary Shares||GB||DKK||Dec 2005|
|4AJ0||DB (Deutsche Boerse AG)||Yes||B Ordinary Shares||DE||EUR||Dec 2005|
|AKBL.F||OTCPK (Pink Sheets LLC)||Yes||B Ordinary Shares||US||USD||Dec 2005|
|ALKBC||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||B Ordinary Shares||GB||DKK||Dec 2005|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.